Information Provided By:
Fly News Breaks for September 7, 2018
CCXI
Sep 7, 2018 | 05:44 EDT
B. Riley FBR analyst Madhu Kumar started ChemoCentryx with a Neutral rating and $12.50 price target. The company's positive Phase II data is balanced by Phase III risk, Kumar tells investors in a research note.
News For CCXI From the Last 2 Days
There are no results for your query CCXI